Alpha Mannosidosis Global Market Report 2021: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global alpha mannosidosis market.
This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the alpha mannosidosis market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the alpha mannosidosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Alpha Mannosidosis market global report from the publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider alpha mannosidosis market, and compares it with other markets.
Scope
Markets Covered:
1) By Therapy Type: Bone Marrow Transplant (BMT); Enzyme Replacement Therapy (ERT); Peripheral Blood Stem Cell Transplantation (PBSCT); Gene Therapy
2) By Indication: Type I; Type II; Type III
3) By End-User: Hospitals; Speciality Clinics
Companies Mentioned: CHIESI Farmaceutici SpA; Nuo Therapeutics; Zymenex
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the alpha mannosidosis market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the alpha mannosidosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Alpha Mannosidosis market global report from the publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider alpha mannosidosis market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The alpha mannosidosis market section of the report gives context. It compares the alpha mannosidosis market with other segments of the alpha mannosidosis market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, alpha mannosidosis indicators comparison.
Scope
Markets Covered:
1) By Therapy Type: Bone Marrow Transplant (BMT); Enzyme Replacement Therapy (ERT); Peripheral Blood Stem Cell Transplantation (PBSCT); Gene Therapy
2) By Indication: Type I; Type II; Type III
3) By End-User: Hospitals; Speciality Clinics
Companies Mentioned: CHIESI Farmaceutici SpA; Nuo Therapeutics; Zymenex
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Alpha Mannosidosis Market
What is the estimated value of the Global Alpha Mannosidosis Market?
What is the growth rate of the Global Alpha Mannosidosis Market?
What is the forecasted size of the Global Alpha Mannosidosis Market?
Who are the key companies in the Global Alpha Mannosidosis Market?
Table of Contents
1. Executive Summary2. Alpha Mannosidosis Market Characteristics3. Alpha Mannosidosis Market Trends and Strategies4. Impact Of COVID-19 On Alpha Mannosidosis28. Key Mergers and Acquisitions In The Alpha Mannosidosis Market29. Alpha Mannosidosis Market Future Outlook and Potential Analysis
5. Alpha Mannosidosis Market Size and Growth
6. Alpha Mannosidosis Market Segmentation
7. Alpha Mannosidosis Market Regional and Country Analysis
8. Asia-Pacific Alpha Mannosidosis Market
9. China Alpha Mannosidosis Market
10. India Alpha Mannosidosis Market
11. Japan Alpha Mannosidosis Market
12. Australia Alpha Mannosidosis Market
13. Indonesia Alpha Mannosidosis Market
14. South Korea Alpha Mannosidosis Market
15. Western Europe Alpha Mannosidosis Market
16. UK Alpha Mannosidosis Market
17. Germany Alpha Mannosidosis Market
18. France Alpha Mannosidosis Market
19. Eastern Europe Alpha Mannosidosis Market
20. Russia Alpha Mannosidosis Market
21. North America Alpha Mannosidosis Market
22. USA Alpha Mannosidosis Market
23. South America Alpha Mannosidosis Market
24. Brazil Alpha Mannosidosis Market
25. Middle East Alpha Mannosidosis Market
26. Africa Alpha Mannosidosis Market
27. Alpha Mannosidosis Market Competitive Landscape and Company Profiles
30. Appendix
Executive Summary
Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex.The global alpha mannosidosis market is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis, use of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment and advancements in treatment drugs. The market is expected to reach $17.91 million in 2025 at a CAGR of 19.1%.
The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis (organizations, sole traders and partnerships) that provides treatment for alpha mannosidosis, which is a lysosomal storage disorder. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Alpha-mannosidosis is a rare genetic inherited condition that affects the organs and tissues of the person suffering from the disease. The treatment therapy focuses on detecting and preventing polysaccharide accumulations within mutant cells, which can cause harm to tissue, organs, and eventually death. Polysaccharides are defined as larger molecules composed of several linked sugar molecules.
The main types of therapy for alpha mannosidosis are bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT) and gene therapy. A bone marrow transplant is a procedure in which dysfunctional marrow is replaced with healthy marrow. Enzyme replacement therapy includes replacing a defective enzyme in people who are lacking or deficient in that enzyme. Peripheral blood stem cell transplantation is a procedure in which the patient whose stem cells that have been destroyed by disease or by the radiation or high doses of anticancer drugs, they receive healthy stem cells. Gene therapy is a procedure in when DNA is introduced into a patient to treat a genetic disease. The different types of indications include Type I, Type II and Type III and is implemented in wide range of verticals such as hospitals and specialty clinics.
North America was the largest region in the alpha mannosidosis market in 2020. Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The advancements in treatment for alpha mannosidosis like pharmacological therapy are gaining traction in the alpha mannosidosis market. For instance, in 2018 - Chiesi Group, an international research-focused Healthcare company, announced that it has received a positive opinion recommending the marketing authorization of Velmanase Alfa, under the brand name Lamzede from the European Medicines Agency Committee for Medicinal Products for Human Use. Lamzede is an enzyme replacement therapy intended to provide or supplement natural alpha-mannosidase, an enzyme that helps with the degradation of mannose-rich oligosaccharides and thus prevents their accumulation in various tissues in the body.
The increasing investments on research is expected to contribute to the growth of the alpha mannosidosis market in the forecast period. Currently, in the alpha mannosidosis market, only one company has therapies for the rare genetic disease. However, several firms have products in the clinical stages, which will boost market demand in the forecast period. For instance, in 2020, the EU clinical trials database lists 39,219 clinical trials with a EudraCT protocol, 6,426 of which are clinical trials involving subjects under the age of 18. Therefore, the increasing investments on research fuels the growth of the alpha mannosidosis market.
The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Companies Mentioned
A selection of companies mentioned in this report includes:
- CHIESI Farmaceutici SpA
- Nuo Therapeutics
- Zymenex
Methodology
LOADING...
